全文获取类型
收费全文 | 24873篇 |
免费 | 1170篇 |
国内免费 | 195篇 |
专业分类
耳鼻咽喉 | 331篇 |
儿科学 | 361篇 |
妇产科学 | 207篇 |
基础医学 | 2811篇 |
口腔科学 | 611篇 |
临床医学 | 1558篇 |
内科学 | 6513篇 |
皮肤病学 | 401篇 |
神经病学 | 2255篇 |
特种医学 | 960篇 |
外科学 | 4356篇 |
综合类 | 115篇 |
预防医学 | 888篇 |
眼科学 | 489篇 |
药学 | 1636篇 |
中国医学 | 47篇 |
肿瘤学 | 2699篇 |
出版年
2023年 | 130篇 |
2022年 | 264篇 |
2021年 | 503篇 |
2020年 | 269篇 |
2019年 | 327篇 |
2018年 | 434篇 |
2017年 | 332篇 |
2016年 | 433篇 |
2015年 | 442篇 |
2014年 | 634篇 |
2013年 | 805篇 |
2012年 | 1222篇 |
2011年 | 1353篇 |
2010年 | 731篇 |
2009年 | 673篇 |
2008年 | 1241篇 |
2007年 | 1296篇 |
2006年 | 1345篇 |
2005年 | 1441篇 |
2004年 | 1353篇 |
2003年 | 1284篇 |
2002年 | 1283篇 |
2001年 | 810篇 |
2000年 | 839篇 |
1999年 | 728篇 |
1998年 | 372篇 |
1997年 | 304篇 |
1996年 | 280篇 |
1995年 | 204篇 |
1994年 | 170篇 |
1993年 | 173篇 |
1992年 | 426篇 |
1991年 | 402篇 |
1990年 | 355篇 |
1989年 | 399篇 |
1988年 | 364篇 |
1987年 | 304篇 |
1986年 | 281篇 |
1985年 | 279篇 |
1984年 | 209篇 |
1983年 | 178篇 |
1982年 | 83篇 |
1979年 | 137篇 |
1978年 | 103篇 |
1977年 | 75篇 |
1974年 | 85篇 |
1973年 | 84篇 |
1972年 | 82篇 |
1971年 | 79篇 |
1969年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
Kensuke Kudou Hiroshi Saeki Yuichiro Nakashima Shun Sasaki Tomoko Jogo Kosuke Hirose Qingjiang Hu Yasuo Tsuda Koichi Kimura Ryota Nakanishi Nobuhide Kubo Koji Ando Eiji Oki Tetsuo Ikeda Yoshihiko Maehara 《American journal of surgery》2019,217(4):757-763
Background
There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).Methods
Patients with AEG and UGC who were judged as non-sarcopenic before surgery were reassessed the presence of postoperative development of sarcopenia 6 months after surgery. Patients were divided into the development group or non-development group, and clinicopathological factors and prognosis between these two groups were analyzed.Results
The 5-year overall survival rates were significantly poorer in the development group than non-development group (68.0% vs. 92.6%, P?=?0.0118). Multivariate analyses showed that postoperative development of sarcopenia was an independent prognostic factor for poor overall survival (P?=?0.0237).Conclusions
Postoperative development of sarcopenia was associated with a poor prognosis in patients with AEG and UGC. 相似文献6.
7.
Hiroto Kinoshita Hitomi Nishioka Aya Ikeda Kyoko Ikoma Yoichi Sameshima Hidehisa Ohi Mizuki Tatsuno Junka Kouyama Chiaki Kawamoto Tomohiro Mitsui Yuko Tamura Yu Hashimoto Masashi Nishio Tsuyoshi Ogashiwa Yusuke Saigusa Shin Maeda Hideaki Kimura Reiko Kunisaki Kazuhiko Koike 《Journal of gastroenterology and hepatology》2019,34(11):1929-1939
8.
9.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
10.
Kazunori Aizawa Takeshi Hanaoka Hiroki Kasai Kaoru Kogashi Setsuo Kumazaki Jun Koyama Hiroshi Tsutsui Yoshikazu Yazaki Noboru Watanabe Osamu Kinoshita Uichi Ikeda 《Hypertension research》2006,29(2):123-128
The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Recently, vardenafil, a more potent and selective PDE-5 inhibitor than sildenafil, has been approved for the treatment of erectile dysfunction. However, the long-term effects of oral vardenafil in patients with PH are unknown. We studied five consecutive patients with PH; one with primary pulmonary hypertension, two with chronic pulmonary thromboembolism, one with Eisenmenger syndrome (ventricular septal defect) and one with secondary pulmonary hypertension after a ventricular septal defect closure operation. In an acute hemodynamic trial, vardenafil (5 mg) significantly decreased both the pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) with an increase in cardiac output. In a chronic hemodynamic trial, the maintenance dose of vardenafil (10 to 15 mg) for 3 months significantly decreased the PVR, but not the SVR, with a 20.7% reduction of the PVR/ SVR ratio. Plasma brain natriuretic peptide (BNP) levels were also significantly decreased after 3 months. This pilot study demonstrates that long-term oral vardenafil therapy may be a safe and effective treatment for patients with PH. 相似文献